Psychedelics in the Workplace: What Employers Need to Know

Medical interest in psychedelics—such as psilocybin, MDMA, and ketamine—is growing rapidly. Psilocybin, found in certain mushrooms, and MDMA, a synthetic compound affecting mood and perception, are being studied alongside ketamine, a legally prescribed anesthetic increasingly used in mental health treatment. Fueled by expanding research, these substances are moving from the margins into mainstream conversation.

While this may still feel distant from day-to-day HR operations, employers are beginning to encounter real workplace questions. As with cannabis a decade ago, the legal and practical implications are evolving, and employers should be paying attention.

A Patchwork Legal Landscape

At the federal level, most psychedelics, including psilocybin and MDMA, remain Schedule I controlled substances, meaning they are currently classified as having no accepted medical use under federal law and have a high potential for abuse.

At the same time, important developments are underway:

• Ketamine is already a legal Schedule III medication, judged to have only moderate abuse potential and dependence risk when prescribed and used in clinical settings.
• The FDA has designated certain therapies (such as MDMA-assisted therapy) as “breakthrough treatments.”
• States and local jurisdictions are beginning to decriminalize or regulate limited use.

The result is a patchwork legal landscape, similar to where cannabis laws stood years ago—rapidly evolving, but far from uniform.

Employers are most likely to encounter psychedelics in a medical or mental health context, including:

• Employees seeking psychedelic-assisted therapy for conditions such as PTSD or depression
• Ketamine treatments prescribed by licensed providers
• Questions about whether treatment is protected or requires accommodation

ADA and Accommodation: The Emerging Issue

As medical use expands, employers should anticipate an increase in accommodation requests tied to mental health treatment. For example, prescription Ketamine therapy for depression (already legal) may trigger accommodation discussions, and potential future approval of MDMA-assisted therapy could further expand requests. This will likely follow a familiar pattern from medical marijuana and may increase scrutiny of blanket “zero tolerance” policies.

Employers should be prepared to engage in the Americans with Disabilities Act (ADA) interactive process as appropriate, evaluating requests on a case-by-case basis with attention to job duties, safety, and functional limitations.

State Spotlight: Oregon and Colorado  

Oregon is the first state to create a regulated psilocybin services program; use is limited to licensed facilities with supervised sessions. For employers, however, there are no workplace protections and no restrictions on discipline or policy enforcement.

Colorado has decriminalized certain psychedelics and created a regulated access framework allowing personal use and licensed “healing centers.” Colorado law includes limited anti-discrimination protections for program participation, but these protections are narrow and do not provide broad employment protections like some state cannabis laws.

Employer Takeaways:  

Although psychedelics are not yet a mainstream workplace issue, they are moving in that direction.

Employers retain the right, and obligation, to:

• Prohibit impairment at work,
• Maintain drug-free workplace policies, and
• Enforce safety standards, particularly in safety-sensitive roles (e.g., positions involving driving, operating machinery, or direct responsibility for others’ safety), where stricter controls and expectations may apply.

However, drug testing for many psychedelics requires targeted, expensive lab analysis, and it is not part of standard 5-panel or 10-panel drug screens. As a result, enforcement of drug-free workplace policies may rely more heavily on observable impairment, employee disclosure, and documented safety concerns or incidents.

Psychedelics are not yet the next major compliance issue—but they are on the horizon. Employers can take a lesson from cannabis: don’t wait for full legalization to revisit policies. Focus on impairment and workplace safety, consistent, case-by-case ADA analysis, and clear alignment with current law.

Members can check out these related mozzo resources: 

• Drug Testing
• Drug Alcohol Impairment Assessment Form
  
• Disability Accommodations
  
• Drug & Alcohol Policy

Not yet a member? Learn more about Archbright Membership and mozzo subscriptions.